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Background. Previously we established two cell lines (SNU MM1393 BM and SNU MM1393 SC) from different tissues (bone
marrow and subcutis) of mice which were injected with single patient’s myeloma sample.We tried to define genetic changes specific
for each cell line using whole exome sequencing (WES).Materials and Methods.We extracted DNA from SNU MM1393 BM and
SNU MM1393 SC and performed WES. For single nucleotide variants (SNV) calling, we used Varscan2. Annotation of mutation
was performed using ANNOVAR. Results. When calling of somatic mutations was performed, 68 genes were nonsynonymously
mutated only in SNU MM1393 SC, while 136 genes were nonsynonymously mutated only in SNU MM1393 BM. KIAA1199, FRY,
AP3B2, andOPTC were representative genes specifically mutated in SNU MM1393 SC.When comparison analysis was performed
using TCGA data, mutational pattern of SNU MM1393 SC resembled that of melanoma mostly. Pathway analysis using KEGG
database showed that mutated genes specific of SNU MM1393 BMwere related to differentiation, while those of SNU MM1393 SC
were related to tumorigenesis.Conclusion.We found out genetic changes that underlie tropismofmyeloma cells usingWES.Genetic
signature of cutaneous plasmacytoma shares that of melanoma implying common mechanism for skin tropism. KIAA1199, FRY,
AP3B2, and OPTC are candidate genes for skin tropism of cancers.
1. Introduction
Multiple myeloma is a malignant B-cell disorder character-
ized by proliferation of atypical plasma cells in bone marrow
[1] with or without the presence ofmonoclonal immunoglob-
ulin protein in serum and/or urine [2].Multiplemyeloma has
correlation with plasmacytoma, which is a mass of plasma
cells found outside of bone marrow [3] that needs medical
intervention with radiotherapy [4] or chemotherapy. While
multiple myeloma frequently accompanies plasmacytoma
at the time of diagnosis, plasmacytoma precedes multiple
myeloma in some cases. The disease entity called solitary
plasmacytoma exists in 4% of plasma cell tumors [5, 6],
and approximately 40–50% of patients with solitary plas-
macytoma will develop multiple myeloma [7]. Hence, plas-
macytoma is an early form or an accompanying disease of
myeloma, and the data regarding the “clinical behavior” of
plasmacytoma are quite accumulated. However, not much is
known about the cellular biology of plasmacytoma per se.
Fortunately, we previously succeeded in establishing two
cell lines with different tropism from a single patient [8].
Briefly, 14 weeks after injecting mononuclear cells obtained
from multiple myeloma patient’s bone marrow in a NRG/
SCID mouse via tail vein, tumor developed at subcutis of
the mouse. The engraftment of myeloma cells into mouse
bone marrow (BM) was also observed. After separation
and culturing cells from subcutis and BM, we succeeded
in the establishing of two cell lines (SNU MM1393 SC and
SNU MM1393 BM) from a single patient with different
tropism.These two cell lines showed different biologic behav-
ior. In contrast to SNU MM1393 BM, cell proliferation of
SNU MM1393 SCwas IL-6 independent. SNU MM1393 BM
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and SNU MM1393 SC showed a high degree of resistance
against bortezomib compared to U266 cell line. SNU
MM1393 BM had the greater lethality compared to SNU
MM1393 SC.
From genetic perspective, we believe that unique somatic
mutations may allow tumor cells to adapt and survive in
tumor microenvironment. In other words, there may be
specific genetic changes that contribute to tumor tropism.
Hence, in this study, we tried to characterize genomic profile
specific for SNU MM1393 BM and SNU MM1393 SC to
understand genetic background of difference in these cell
lines. We were particularly interested in genetic changes
specific for SNU MM1393 SC, because we thought these
SNU MM1393 SC specific genetic changes would reveal
genetic background for plasmacytoma which exhibit tropism
for extramedullary space. To find these genetic changes, we
performed whole exome sequencing (WES) using DNA of
both cell lines. As it is well known, WES allows compre-
hensive characterization of genomic changes in individual
tumors [9].
2. Materials and Methods
2.1. DNA Preparation and Whole Exome Sequencing. DNA
was extracted from two cell lines (SNU MM1393 BM and
SNU MM1393 SC). QuickGene DNA whole blood kit S
(Kurabo Industries Ltd., Japan) was used to extract DNA
according to themanufacturer’s recommendations. ForWES,
we sequenced exome using the Solexa sequencing technology
platform (HiSeq2000, Illumina, SanDiego, CA, USA) follow-
ing the manufacturer’s instructions. We randomly sheared
3 ug of genomic DNA using Covaris System to generate
about 150 bp inserts. The fragmented DNA was end-repaired
using T4 DNA polymerase and Klenow polymerase, and
Illumina paired-end adaptor-oligonucleotides were ligated
to the sticky ends. We analyzed the ligation mixture by
electrophoresis on an agarose gel, sliced and purified frag-
ments with 200–250 bp sizes. Purified DNA library was
hybridized with SureSelect Human All Exon V4 probes set
(Agilent, Santa Clara, CA, USA) to capture 50Mb targeted
exons following manufacturer’s instruction. We prepared
the HiSeq2000 paired-end flow cell to the manufacturer’s
protocol using captured exome library. Clusters of PCR
colonies were then sequenced on the HiSeq2000 platform
using recommended protocols from the manufacturer.
2.2. Alignment of FASTQ File. FASTQ files were aligned
to human reference (human g1k v 37.fasta) by using the
Burrows-Wheeler aligner (BWA-0.7.5) [10] to make SAM file.
SortSam in Picard-tools-1.68 was used to convert to BAM file
and sortwith chromosome andwent through aPCRduplicate
marking process, which enables theGenomeAnalysis Toolkit
(GATK-1.6.5) to ignore duplicates in subsequent processing
[11]. We performed a local realignment prior to recalibration,
which gives the most accurate quality scores for each sample.
Recalibration was performed to increase recalibration accu-
racy. A default value was set for all processes.
2.3. Variant Calling and Annotation. For single nucleotide
variant (SNV) and small indel calling, we used Varscan2
(http://genome.wustl.edu/) [12]. Because germline control
was absent, we used pilup2snp command for single sample
calling using human g1k v 37 as reference genome.We set the
following options: (1) minimum coverage above value of 20,
(2) minimum variant allele frequency above value of 0.1, and
(3) default𝑝 value below 0.05 other option value set as default
values. To select uniquemutation, we performed comparison
between two calling results. For functional annotation and
prediction of variant effect, we used ANNOVAR [13] with
Polyphen [14] database version 2.2.2.
2.4. Use of Public Database as a Reference. For comparing
public data with results in this study, we used datasets from
TCGA (https://tcga-data.nci.nih.gov/tcga/tcgaHome2.jsp),
cBioPortal for CancerGenomics (http://www.cbioportal.org/
public-portal/), and KEGG database for pathway analysis
(http://david.abcc.ncifcrf.gov/).
3. Results
3.1. Tumor Purity, Alignment, andCoverage Statistics. FastQC
toolkit was used for statistical analysis. The raw data size of
SNU 1393MM BMand SNU 1393MM SCwas 9,090MB and
8,979MB, respectively. Approximately 99.00% of the targeted
reads (165483843 reads) were covered sufficiently to pass our
thresholds for calling variants (MAPQ > 20 by NGS QC
Toolkitv2.3). MAPQ distribution following that above 30 was
98.2% (164088367), above 20 was 0.8% (1395476), and below
20 of MAPQ was under 10%. For SNU 1393MM SC, MAPQ
distribution following that above 30 was 98.1% (159871347),
above 20 was 0.8% (154084), and below 20 of MAPQ was
around 10%.
3.2. Somatic Mutation Calling Summary. When SNV calling
was performed using Varscan, a total of 18573 SNVs were
found in SNU MM1393 SC. Their distribution according to
the functional consequences was as follows: 8595 (46.2%)
nonsynonymous, 9575 (51.5%) synonymous, 68 (0.003%)
stop-gain, and 6 (0.0003%) stop-loss. In SNU MM1393 BM,
a total of 18781 SNVs were found and their distribution
was as follows: 8694 (46.2%) nonsynonymous, 9667 (51.5%)
synonymous, 75 (0.004%) stop-gain, and 5 (0.0003%) stop-
loss. As for nonsynonymous SNVs, we found 8595 nonsyn-
onymous SNVs in 4901 genes for SNU MM1393 SC, while
8694 nonsynonymous SNVs in 4969 genes were found in
SNU MM1393 BM. There was overlapping of 8344 nonsyn-
onymous SNVs, and 251 nonsynonymous SNVs and 350
nonsynonymous SNVs were unique for SNU MM1393 SC
and SNU MM1393 BM, respectively (Figures 1(a)–1(c)).
The rate of transversion and transition in the coding
region was different between the two cell lines. While trans-
version was dominant event in SNU MM1393 BM cell line,
transition was dominant event in SNU MM1393 SC. Abso-
lute transversion rate was much higher in SNU MM1393 BM
(65.5%) than SNU MM1393 SC (34.0%) (Figure 1(d)).































3.3. Comparison of Genomic Signature Using Public Database.
After calling of SNVs, we compared genomic signatures
of SNU MM1393 SC and SNU MM1393 BM with those
of tumors in public database. For this comparison, we
selected 12 nonsynonymous SNVs that is unique for
SNU MM1393 BM and 11 nonsynonymous SNVs that is
unique for SNU MM1393 SC. These SNVs were selected
according to the criteria below: with the assumption that two
cell lines consisted of single cell population, we selected genes
with variant allele frequency between 0.4 and 0.6. First, the
frequencies of these SNVs were investigated in open source
data of multiple myeloma (Multiple Myeloma Research
Consortium) [15] using cBioportal for Cancer Genomics
(http://www.cBioportal.org). Around half of SNVs found in
our cell lines were found with low frequency (0.5–2%) in
open source database of multiple myeloma (Table 1).
Then, the frequencies of these SNVs were investigated
in open source data of various cancers (http://www.cBio-
portal.org). When this analysis was performed, SNVs which
are unique for SNU MM1393 SC were frequently detected in
melanoma (52.8%) and uterine cancer (49.0%). On the other
hand, SNVs those which are unique for SNU MM1393 BM
were frequently found in ovarian cancer (74.7%) and bladder
cancer (72.8%) (Figure 2).
3.4. Monte Carlo Simulation and Pathway Analysis. Using
Monte Carlo Simulation (Ratio of dNs/dS), we examined
distribution statistics of SNVs found in two cell lines, respec-
tively. It is believed that nonrandomness of SNV distribution
is related to the functional importance of those SNVs. When
this analysis was performed, ratio for SNU MM1393 BMwas
2.8 (𝑝 = 0.14), while it was 1.1 for SNU MM1393 SC (𝑝 =
0.07). Hence, SNV distribution in both cell lines was random
with cut-off 𝑝 value of 0.05. Our results indicated that unique
nonsynonymous mutations of SNU MM1393 SC seemed
biologically more neutral than those of SNU MM1393 BM
although they were statistically insignificant.
In KEGG pathway analysis of unique somatic mutation
from both cell lines, the result of pathway analysis showed
both similarities and differences. Chemokine signaling path-
way and chemokine-chemokine interaction pathway were
showed in two cell lines at the same time.While tight junction
and adherens junction were shown to be involved only
in SNU MM1393 SC, SNU MM1393 BM cell line showed
diverse disorder in pathway such as cell cycle, Wnt signaling
pathway, and MAPK signaling pathway (Figure 3).
4. Discussion
In this report, we analyzed genomic signature of two cell
lines derived from single patient. These cell lines have
different tropism, and SNU MM1393 SC is plasmacytoma
which has tropism for skin.Thus,we thought this studywould
reveal genetic changes that are related to skin tropism and
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Table 1: Gene list of two cell lines.
Gene symbol Chromosome Protein change Functional effect Variant type Frequency in cBioportal∗
SNU MM1393 BM
NEK2 1 N→ S Benign Nonsynonymous SNV 0%
IARS2 1 None None Nonsynonymous SNV 0%
OR2T33 1 P→ L Possibly damaging Nonsynonymous SNV 0%
PPIG 2 D→E Benign Nonsynonymous SNV 1%
AOX1 2 None None Nonsynonymous SNV 1%
TMEM129 4 None None Nonsynonymous SNV 0%
UNC5CL 6 R→G Benign Nonsynonymous SNV 0%
ARHGEF10 8 None None Nonsynonymous SNV 2%
H1FNT 12 R→Q Benign Nonsynonymous SNV 1%
ZIC2 13 None None Nonsynonymous SNV 0%
TMX1 14 None None Nonsynonymous SNV 0%
PANK2 20 G→A Benign Nonsynonymous SNV 0%
SNU MM1393 SC
RBM15 1 None None Nonsynonymous SNV 0.50%
OPTC 1 L→P Benign Nonsynonymous SNV 0%
OR5H1 3 T→ I Possibly damaging Nonsynonymous SNV 0%
MRPL23 11 D→N Benign Nonsynonymous SNV 0%
FRY 13 None None Nonsynonymous SNV 1%
KIAA1199 15 None None Nonsynonymous SNV 0%
AP3B2 15 None None Nonsynonymous SNV 1%
IL27 16 L→P Probably damaging Nonsynonymous SNV 0%
KIF1C 17 None None Nonsynonymous SNV 1%
ZNF486 19 None None Nonsynonymous SNV 0%
ARSE X None None Nonsynonymous SNV 1%
∗cBioportal data of multiple myeloma.
plasmacytoma. In fact, recent study reported the process of
segregation of genetic changes in tumor cells during clonal
expansion [16]. As far as we know, this is the first WES study
comparing the genomics of myeloma cells in bone marrow
and plasmacytoma. Varscan2 which was used in our study
for somatic variant calling is one of the most commonly used
tools to detect somatic mutation along with MuTect [12, 17].
In fact, many papers already published in the field of cancer
genomics already used Varscan2 [18–20].
As expected, most of SNVs (96.5%) overlapped between
the cell lines, suggesting their common originality from a
single patient. And the most coding sequence SNVs in both
SNU MM1393 BM and SNU MM1393 SC were neutral with
respect to adaptation and cancer cell growth.This is also sup-
ported by the outcome ofMonte Carlo Simulation, where dis-
tribution of SNVs did not show significant nonrandomness.
It has been suggested that bone marrow microenvironment
strictly regulates the growth of cell via dynamic interplay
among hematopoietic cells [21]. And our results indicate that
only a small subset of nonsynonymous SNVs in cancer are
affected by selection, making it possible to interpret SNV
trends as reflection of underlying mutational processes.
The most interesting finding in our data is related to the
genetic changes unique for SNU MM1393 SC. We conjec-
tured in the planning of this study that genetic change unique
for SNU MM1393 SC would be related to skin tropism and
formation of plasmacytoma. And, as expected, genomic
signature that is unique to SNU MM1393 SC had more than
50% of overlapping with melanoma which is a primary skin
tumor.This finding highly coincides with our conjecture and
SNVs such as KIAA1199, FRY, AP3B2, and OPTC may be
the very gene related to skin tropism of cancers. These 4
are the genes that are mutated in SNU MM1393 SC and are
frequently found in melanoma samples. In fact, it has been
known that there are common genetics between melanoma
and plasmacytoma such as CDKN2A germline mutation in
prenext generation sequencing (NGS) era [22].
One more noticeable finding in our study is that the
number of SNVs was higher in SNU MM1393 BM than
in SNU MM1393 SC and transversion rate was higher in
SNU MM1393 BM than in SNU MM1393 SC. Also dynamic
gene to gene interaction in SNU MM1393 BM was more
complex than that in SNU MM1393 SC. Along with this
phenomenon and from the previous report that the number
and pattern of somatic SNVs determine pathway underling
cancer [23], we think that it would be biologically simpler
to form a tumor in subcutis than to form a tumor in bone
marrow in animal xenograft model used in our experiment.
We think this is related to the fact that growth and differen-
tiation of cancer cells in bone marrow are strictly regulated
by dynamic interplay among various hematopoietic cells,
compared to subcutis.
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Ubiquinone and other terpenoid-quinone biosynthesis
Valine, leucine and isoleucine degradation
Autoimmune thyroid disease
ABC transporters
Intestinal immune network for IgA production
Hypertrophic cardiomyopathy (HCM)
Wnt signaling pathway






Biosynthesis of unsaturated fatty acids
Viral myocarditis
Small cell lung cancer
Insulin signaling pathway
Renal cell carcinoma
Antigen processing and presentation
















Type I diabetes mellitus
Protein export
Pyrimidine metabolism
Vascular smooth muscle contraction
Jak-STAT signaling pathway
Leukocyte transendothelial migration
Nicotinate and nicotinamide metabolism
Glycerophospholipid metabolism









In fact, we had difficulties in the analysis ofWES data due
to the lack of germline reference DNA in this study. Because
we used public germline database as reference in the calling
of SNVs, the number of SNVs was very large compared to the
previous multiple myeloma genomic studies. Moreover, it is
well known that themajority ofmutations observed in cancer
sequencing studies are believed to be passenger mutations
having little impact on the cancer cell [24]. To overcome this
issue, we did not focus on the specific genetic changes found
in our study. Rather, we analyzed the “pattern” of genetic
changes found in our study and compared them with public
database so as to find out genetic clues underlying tropism for
International Journal of Genomics 7
skin and plasmacytoma. And this is also the reason why we
focused on the “unique” SNVs for both SNU MM1393 BM
and SNU MM1393 SC instead of whole genomic picture of
SNU MM1393 BM and SNU MM1393 SC.
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